First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

Cancer

Volumn 83, Issue 10, 1998, Pages 2083-2090

  Kourousis, Charalambos ^a   Androulakis, Nicos ^a   Kakolyris, Stelios ^a   Souglakos, John ^a   Maltezakis, George ^a   Metaxaris, George ^a   Chalkiadakis, George ^a   Samonis, George ^a   Vlachonikolis, John ^a   Georgoulias, Vassilis ^a,b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Chemotherapy; Docetaxel; Nonsmall cell lung carcinema; Vinorelbine

Indexed keywords

DOCETAXEL; NAVELBINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; PATIENT COMPLIANCE; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; VINBLASTINE;

EID: 14444270379     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19981115)83:10<2083::AID-CNCR6>3.0.CO;2-I     Document Type: Article

References (30)

1. Mountain CF. Prognostic implications of the International Staging System for Lung Cancer. Semin Oncol 1988;15:236-45.
2. Rigas JR, Kris MG. New chemotherapeutic agents in lung cancer. In: Roth JA, Cos JD, Hong WK, editors. Lung cancer. Cambridge, UK: Blackwell Scientific Publications, 1993:252-69.
3. Donnadieu N, Paesmans M, Sculler JP. Chimiotherapie des caucers bronchiques non a petites cellules. Meta-analyse de la litterature eu fouction de l'extension de la maladie. Rev Mal Respir 1991;8:197-204.
4. Rapp E, Patter JL, Willan A, Cormier Y, Murray N, Evans WK, et al. Chemotherapy can prolong survival in patients with advanced non-small cell lung cancer: report of a Canadian multi-center randomized trial. J Clin Oncol 1988;6:633-41.
5. Stewart LA, for the Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br J Med 1995;311:899-909.
6. Souquet PJ, Chauvin F, Boissel JP, Cellerino R, Cormier Y, Gan PA, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21.
7. Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, Van Meerbeek, et al. Docetaxel (Taxotere) is active in non-small cell lung cancer: a phase II trial of EORTC Early Clinical Trials Group (ECTG). Br J Cancer 1994;70:384-7.
8. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 1995;75:968-72.
9. Francis PA, Rigas JR, Kris MG, Pisters KM, Orazem GP, Wooley KJ, et al. Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. J Clin Oncol 1994;12:1232-7.
10. Fossella FV, Lee JS, Berille J, Hong WH. Summary of phase II data of docetaxel (Taxotere), an active agent in the first-and second-line treatment of advanced non-small cell lung cancer. Semin Oncol 1995;22(Suppl 4):22-9.
11. Le Chevalier T. Docetaxel: meeting the challenge of non-small cell lung cancer management. Anticancer Drugs 1995; 6(Suppl 4):13-7.
12. Depeirre A, Lemarie E, Dabouis G, Gamier G, Jacoulet P, Dalphin JC. A phase II study of navelbine (Vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9.
13. Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 1994;11: 385-91.
14. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their amimitotic activity. J Med Chem 1991;34:992-8.
15. Ringel I, Horwitz SB. Studies with RP-56976 (Taxotere): a semi-synthetic analogue of taxol. J Natl Cancer Inst 1991;83: 288-91.
16. Zavala F, Guenard D, Potier P. Interaction of vinblastine analogues with tubulin. Separatium Experiential 1978;34: 1497-8.
17. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
18. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1985;53:457-81.
19. Liu R. Chemotherapy outcomes in advanced non-small cell lung carcinoma. Semin Oncol 1993;21:296-301.
20. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
21. Depierre A, Chastang CL, Quoix E, Lebeau B, Blanchon F, Paillot N, et al. Vinorelbine versus Vinorelbine plus cisplatin in advanced non-small-cell lung cancer. A randomised trial. Ann Oncol 1994;5:37-42.
22. Wozniak AJ, Kromlay JJ, Balcerzak GR, Weiss LH, Laufman LH, Baker LH, et al. Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC): report of a Southwest Oncology Group study (SWOG-9308). Proc Am Soc Clin Oncol 1996;15:374.
23. Vokes EE, Drinkard LC, Samuels BL, Hoffman PC, Walson S, Bitran JD, et al. A phase II study of Cisplatin, 5-Fluorouracil, leucovorin augmented by vinorelbine (Navelbine) for advanced non-small-cell lung cancer. Rational and study design. Semin Oncol 1994;21(Suppl 8):87-92.
24. Baldini E, Tibaldi C, Chella A, Angeletti CA, Romanini A, Andrei A, et al. Combination chemotherapy with vinorelbine, ifosfamide and cisplatin: a phase II in stage IIIB-IV non-small-cell lung cancer. Semin Oncol 1994;21(Suppl 4): 12-5.
25. Monnier A, Riviere A, Douillard JY, Milleron B, Lemarie E, Trillet-Lenoir V, et al. Phase II study of docetaxel (Taxotere) and Vinorelbine in chemotherapy naive patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1996;15:378.
26. Chang AY, Garrow GC. Pilot study of vinorelbine (Navelbine) and paclitaxel (Taxol) in patients with refractory breast and lung cancer. Semin Oncol 1995;22:66-71.
27. Viallet J, Laberge F, Martins H, Maksimiu KA, Rapp E, Belanger K, et al. A phase II trial of docetaxel alternating with cisplatin and vinorelbine in non-small-cell lung cancer. Proc ESMO. Ann Oncol 1996;7(Suppl 5):93.
28. Van Zandwijk N, ten Bokkel Huinink WW, Wanders J, Simonetti G, Dubbelman R, Franklin H, et al. Dose-finding studies with carboplatin, ifosfamide, etoposide, and mesna in advanced non-small-cell lung cancer. Semin Oncol 1990; 17(Suppl 2):16-9.
29. Seidman AD, Norton L, Reichman BS, Grown JP, Yao TJ, Heelan R, et al. Preliminary experience with taxol plus recombinant human granulocyte colony stimulating factor in the treatment of breast cancer. Semin Oncol 1993;20(Suppl 3):40-5.
30. Pronk LC, Stoter G, Verweij J. Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 1995;21:463-78.